Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

BACKGROUND: We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). METHODS: COUGH-1 (NCT03449134) and COUGH-2 (NCT03449147) are...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ERJ Open Res
Main Authors: Muccino, David R., Morice, Alyn H., Birring, Surinder S., Dicpinigaitis, Peter V., Pavord, Ian D., Assaid, Christopher, Kleijn, Huub Jan, Hussain, Azher, La Rosa, Carmen, McGarvey, Lorcan, Smith, Jaclyn A.
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2020
Assuntos:
Study Protocols
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7682670/
https://ncbi.nlm.nih.gov/pubmed/33263037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00284-2020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados